Neuraxis Inc
neuraxis.comWhat Do They Do?
Sells IB-Stim, a nerve-stimulation device for digestive pain, and RED, a rectal-function test, to hospitals and healthcare providers.
10-K for FY2025, filed Mar 19, 2026Neuraxis, Inc. (“we”, “us”, the “Company” or “Neuraxis”) is a first-to-market growth-stage medical technology company focused on…View ↗
Our first product, IB-Stim, is a PENFS technology intended to be used in patients 8 years and older with functional abdominal pain…View ↗
Our second product, REDTM (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel…View ↗
IB-Stim is indicated for patients 8 years and older suffering from functional abdominal pain, functional dyspepsia (FD),and associated FD…View ↗
How Do They Make Money?
Healthcare companies, mainly hospitals and clinics, buy IB-Stim; Neuraxis is paid after the devices arrive, with invoices typically due within 30 days.
10-K for FY2025, filed Mar 19, 2026Our revenue is derived from the sale of IB-Stim to healthcare companies, primarily hospitals and clinics. Sales generally are not seasonal…View ↗
The Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer’s destination…View ↗
Payment for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer…View ↗
$3.6M
-
10-K for FY2025, filed Mar 19, 2026
$3.6M ↗
Who Are Their Customers?
Customers are primarily children’s hospitals, with adult gastroenterologists and adult pain physicians also among its target customers. NeurAxis markets through a direct sales team and online, and reaches clinicians through affiliated academic societies.
10-K for FY2025, filed Mar 19, 2026
Do Revenues Turn Into Profits?
No. It lost $7.8M in FY2025.
10-K for FY2025, filed Mar 19, 2026
−$7.8MView ↗
10-K for FY2025, filed Mar 19, 2026
−$7.8MView ↗
10-K for FY2025, filed Mar 19, 2026
−$6.5MView ↗
How Are They Changing?
Loading...
